- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01188512
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
A Phase 1, Single Centre, Dose-escalating, Placebo-controlled Study of a Genetically Modified B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Male Volunteers
The purpose of this study is to evaluate the safety and immunogenicity of a new live attenuated vaccine against whooping-cough. It is a phase1, single centre, dose-escalating, placebo-controlled study on a genetically modified B. pertussis strain given as a single intranasal dose to healthy adult male volunteers.
Effective vaccines are needed to protect young infants (from 0 to 6 months, today the most vulnerable age group), preferably after a single administration very early in life. The successful outcome of this project would constitute an important milestone towards nasal vaccination of infants, possibly at birth with a novel, single-dose pertussis vaccine. Our ultimate aim is to protect infants in the most vulnerable age group, before the regular vaccination schedule using already available vaccines is applied. The ultimate aim is thus not to replace current vaccination schedules with available vaccines, but to add a first nasal vaccination to protect very early in life.
Panoramica dello studio
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Solna, Svezia, 171 76
- Karolinska University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Subject will be included in the study if he meets all the following criteria:
- Healthy male born between 1979 and 1991 who has not experienced clinical pertussis (lab. Verified) during the past 10 years and who has not been vaccinated with any pertussis vaccine.
- Informed consent form signed by the subject.
- Subject shall be able to attend all scheduled visits and to understand and comply with the study procedures (e.g. able to read and write Swedish).
Exclusion Criteria:
If any of the following criteria are met, the subject must not be included in the study:
- Individuals with pertussis toxin serum IgG antibodies ≥20 units/mL.
- Blood pressure after resting ≥ 150/90 mmHg.
- Heart rate after resting ≥80 bpm.
- Respiratory rate after resting ≥ 20/minute.
- Unwillingness to refrain from the use of nicotine products from screening through day 28.
- Use of narcotic drugs/alcohol and/or a history of previous use of drug/alcohol abuse whitin the past 2 years prior to screening
- The subject has donated blood or suffered from blood loss of at least 450 ml (1 unit of blood) within 60 days prior to screening or donated plasma within 14 days prior to screening.
- Receipt of immunoglobulin, blood derived products, systemic corticosteroids or other immunosuppressant drugs within 90 days prior to day 0.
- Use of corticosteroids in the respiratory tract(e.g. nasal steroids, inhaled steroids) whitin 30 days prior to day 0.
- Use of herbal medications or dietary supplements within 7 days prior to day 0 at the discretion of the investigator. Unwillingness to refrain from herbal medications or dietary supplements within 30 days after day 0 at the discretion of the investigator.
- Receipt of a vaccine within the last 30 days prior to day 0 or planned vaccination within the next 30 days after day 0.
- Evolving encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of any vaccine.
- Known hypersensitivity to any component of the study vaccine.
- Current participation in any other clinical trial or participation (and during the whole study) in any clinical trial in the previous 3 months prior to day 0.
- Inability to adhere to the protocol, including plans to move from the area.
- Family history of congenital or hereditary immunodeficiency (first degree).
- Infection with HIV, hepatitis B or C.
- Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
- Clinically significant abnormal laboratory values at the discretion of the investigator.
- Person in frequent contact with children less than 1 year of age (father, childcare worker, nurse, etc…) or residence in the same household as persons with known immunodeficiency.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: Placebo
Tampone di formulazione
|
Individuals will get placebo once intranasally.
Dose 2 x 0.1 mL (0.1 mL per nostril).
|
Sperimentale: BPZE1 - Low dose
1,000 colony forming units (cfu) of BPZE1
|
Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
|
Sperimentale: BPZE1- middle dose
100,000 colony forming units (cfu) of BPZE1
|
Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
|
Sperimentale: BPZE1 - High dose
10,000,000 colony forming units (cfu) of BPZE1
|
Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
General safety and local tolerability in the respiratory tract of a single ascending dose of the genetically modified B. pertussis strain
Lasso di tempo: 6 months
|
To determine
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Attachment of the BPZE1 strain to the nasopharyngeal mucosa
Lasso di tempo: Up to 50 days after vaccination
|
Detection of colonizing BPZE1 bacteria in nasopharyngeal culture
|
Up to 50 days after vaccination
|
Immunogenicity
Lasso di tempo: 6 months
|
Immune responses will be determined by serum IgG and IgA, IgG and IgA in saliva and nasopharyngeal aspirate, cytokines and numbers of effector and memory T and B cells after stimulation with the various B. pertussis antigens.
|
6 months
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Nabil Al-Tawil, MD, PhD, Karolinska Trial Alliance
- Direttore dello studio: Camille Locht, PhD, Institut National de la Santé Et de la Recherche Médicale, France
- Investigatore principale: Rigmor Thorstensson, PhD, Swedish Institute for Infectious Disease Control
Pubblicazioni e link utili
Pubblicazioni generali
- Feunou PF, Ismaili J, Debrie AS, Huot L, Hot D, Raze D, Lemoine Y, Locht C. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008 Oct 23;26(45):5722-7. doi: 10.1016/j.vaccine.2008.08.018. Epub 2008 Aug 30.
- Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, Creusy C, Engle J, Goldman WE, Locht C. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2006 Jul;2(7):e65. doi: 10.1371/journal.ppat.0020065.
- Mielcarek N, Debrie AS, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol. 2010 Mar;17(3):317-24. doi: 10.1128/CVI.00322-09. Epub 2010 Jan 27.
- Skerry CM, Cassidy JP, English K, Feunou-Feunou P, Locht C, Mahon BP. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol. 2009 Sep;16(9):1344-51. doi: 10.1128/CVI.00082-09. Epub 2009 Jul 22.
- Kavanagh H, Noone C, Cahill E, English K, Locht C, Mahon BP. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy. 2010 Jun;40(6):933-41. doi: 10.1111/j.1365-2222.2010.03459.x. Epub 2010 Feb 22.
- Jahnmatz M, Amu S, Ljungman M, Wehlin L, Chiodi F, Mielcarek N, Locht C, Thorstensson R. B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial. Vaccine. 2014 Jun 5;32(27):3350-6. doi: 10.1016/j.vaccine.2014.04.048. Epub 2014 Apr 29.
- Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergstrom J, Ljungman M, Torner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014 Jan 8;9(1):e83449. doi: 10.1371/journal.pone.0083449. eCollection 2014.
- Schnoeller C, Roux X, Sawant D, Raze D, Olszewska W, Locht C, Openshaw PJ. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med. 2014 Jan 15;189(2):194-202. doi: 10.1164/rccm.201307-1227OC.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BT06-04
- 2010-019936-11 (Numero EudraCT)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Pertosse
-
University Hospital, GhentGlaxoSmithKline; Sanofi Pasteur, a Sanofi Company; Novartis Vaccines; University... e altri collaboratoriCompletatoPrevenzione delle infezioni da Bordetella PertussisBelgio
-
University of VirginiaSconosciutoTrasporto di Bordetella PertussisStati Uniti
-
DiaSorin Molecular LLCNon ancora reclutamentoMalattia di coronavirus 2019 | Influenza A | Virus respiratorio sinciziale (RSV) | Adenovirus | Influenza di tipo B | Enterovirus | Polmonite da micoplasma | Infezione da Bordetella Parapertussis | Polmonite da clamidia | Parainfluenza | Infezione respiratoria da Bordetella PertussisAustralia
Prove cliniche su BPZE1
-
National Institute of Allergy and Infectious Diseases...CompletatoPertosse | Immunizzazione contro la pertosseStati Uniti
-
Institut National de la Santé Et de la Recherche...CompletatoPertosse | PertosseSvezia
-
ILiAD BiotechnologiesAttivo, non reclutanteBordetella pertosse, pertosseRegno Unito, Australia, Costa Rica
-
ILiAD BiotechnologiesPPDCompletatoPertosse | PertosseStati Uniti
-
ILiAD BiotechnologiesCompletatoPertosse/pertosse | Bordetella pertosse, pertosseRegno Unito